甘李藥業(603087.SH):上半年預虧1.68億元-2.0億元
格隆匯7月14日丨甘李藥業(603087.SH)公佈,公司預計2022年半年度實現歸屬於上市公司股東的淨利潤為-2.0億元到-1.68億元,與上年同期相比,將出現虧損。公司業績預計2022年半年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤為-2.10億元到-1.80億元。
公司營業收入主要來源於胰島素製劑產品的銷售收入。公司在2021年國家組織的第六批國家藥品集採(胰島素專項)中,公司六款產品均高順位中標。公司在獲得較高的協議採購量的同時,產品價格下降明顯。由於集採執行時間較短,短期內銷量的增長尚不能對沖價格下降的影響。另外,2022年5月,集採中選結果在全國各省市開始陸續執行,部分商業客户進行庫存控制與調整。以上是導致公司本期營業收入降幅較大的主要原因。
公司藉助在集採中獲得的價格優勢以及協議採購量、醫療機構的資源優勢,加速提升公司產品的市場滲透率,在本期快速擴增學術推廣團隊規模並繼續加大相關投入,因此銷售費用同比增長。儘管本期公司營業收入受到集採影響,但公司各項研發工作依然正常推進,本期研發費用同比上漲。
綜上所述,公司本期營業收入下降、銷售費用及研發費用保持繼續上漲的態勢,公司利潤下降較為明顯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.